Malignant News and Research

RSS

Research examines tumor-initiating events that lead to pancreatic cancer

A diagnosis of pancreatic cancer is particularly devastating since the prognosis for recovery is usually poor, with the cancer most often not detected until late stages.

30 Nov 2012

Vermillion’s OVA1 diagnostic test effectively identifies early-stage ovarian cancer

Gynecologic Oncology, the prestigious medical journal of the Society for Gynecologic Oncology, has published the second prospective clinical study of OVA1 which demonstrated the positive performance of the multi-biomarker test in the triage of early-stage ovarian cancer.

29 Nov 2012

Neurofibromatosis-1 may increase risk of breast cancer in women

New Johns Hopkins research showing a more than four-fold increase in the incidence of breast cancer in women with neurofibromatosis-1 (NF1) adds to growing evidence that women with this rare genetic disorder may benefit from early breast cancer screening with mammograms beginning at age 40, and manual breast exams as early as adolescence.

27 Nov 2012

Weill Cornell Medical College dean wins Argentina's Dr. Luis Federico Leloir Prize

Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and provost for medical affairs of Cornell University, is a winner of the Dr. Luis Federico Leloir Prize of International Cooperation in Science, Technology and Innovation from Argentina's Ministry of Science, Technology and Productive Innovation.

27 Nov 2012

Researchers discover molecular basis for potential cancer preventive effects of vitamin D

A team of researchers at McGill University have discovered a molecular basis for the potential cancer preventive effects of vitamin D. The team, led by McGill professors John White and David Goltzman, of the Faculty of Medicine's Department of Physiology, discovered that the active form of vitamin D acts by several mechanisms to inhibit both the production and function of the protein cMYC.

26 Nov 2012

Cancer-killing viruses found safe but less effective than expected

Doctors now use cancer-killing viruses to treat some patients with lethal, fast-growing brain tumors. Clinical trials show that these therapeutic viruses are safe but less effective than expected.

26 Nov 2012

Bowel cancer and GIST patients could benefit from novel oral drug

Two phase 3 trials, published in The Lancet, have shown that a novel oral drug called regorafenib could offer survival benefits to people with bowel (colorectal) cancer or gastrointestinal stromal tumour (GIST) following failure of existing treatments.

22 Nov 2012

Regorafenib able to control resistant gastrointestinal stromal tumor

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.

21 Nov 2012

Uninsured patients could be twice as likely to die after brain cancer surgery

Uninsured patients who undergo surgery to remove a brain tumor could be twice as likely to die in the hospital as those who have the same operation but are privately insured, new Johns Hopkins research suggests. In teaching hospitals, where most neurosurgical procedures take place, those with government-subsidized insurance in the form of Medicaid were found in the same study to have rates of survival closer to those who are privately insured.

20 Nov 2012

Combination of perifosine and temsirolimus shows promise against malignant glioma

Aeterna Zentaris Inc. today announced that perifosine, its oral AKT inhibitor, combined with temsirolimus ("TEM"), was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma ("MG").

20 Nov 2012

Cancer Network, ONCOLOGY present two part primer report on targeted therapies in solid tumors

UBM Medica US announces that Cancer Network and the journal ONCOLOGY are presenting a two part primer report on targeted therapies in solid tumors.

17 Nov 2012

Fibulin-3 effective biomarker for pleural mesothelioma

Research suggests that levels of fibulin-3 in plasma and effusions may aid in determining the diagnosis and prognosis of pleural mesothelioma.

16 Nov 2012

New software improves accuracy of breast thermography in detection of cancer

Straightforward imaging with an infrared, thermal, camera for detecting breast cancer early without the discomfort or inconvenience of mammography or biomolecular tests, according to a study to be published in the International Journal of Innovative Computing and Applications.

15 Nov 2012

Scientists eliminate metastasis in laboratory experiments

In laboratory experiments, scientists have eliminated metastasis, the spread of cancer from the original tumor to other parts of the body, in melanoma by inhibiting a protein known as melanoma differentiation associated gene-9 (mda-9)/syntenin. More than 1 million cases of skin cancer are diagnosed each year in the U.S., and melanoma is the deadliest form.

15 Nov 2012

Medulloblastomas that arise from different cell types might require personalized treatments

Cancers arise when a normal cell acquires a mutation in a gene that regulates cellular growth or survival. But the particular cell this mutation happens in-the cell of origin-can have an enormous impact on the behavior of the tumor, and on the strategies used to treat it.

14 Nov 2012

Patients with gastric cancer have impaired TGFβig-h3 protein

Scientists at the University of Liverpool have found that the production of a protein that prevents the growth and spread of cancerous cells is impaired in patients with gastric cancer.

14 Nov 2012

IDMC reviews data from Nanobiotix’s NBTXR3 Phase I study on advanced soft tissue sarcoma

Nanobiotix, announced today that the Independent Data Monitoring Committee (IDMC) has reviewed the data of the first 6 patients treated in the phase I Study with the lead product NBTXR3 for the treatment of advanced Soft Tissue Sarcoma of the extremity. Based on the review of the safety data, the IDMC has unanimously recommended continuing the enrollment in the study according to the protocol. This trial is realized in the Institut Gustave Roussy, France.

13 Nov 2012